COVID-19 Tedavisinde Antiviral İlaçlar: Klinik Çalışmalar Işığında Güncel Antiviral Farmakoterapi
Referanslar
Tanriverdi ES, Yakupoğulları Y, Otlu B. COVID-19 etkeninin özellikleri. In: Çiçek C (ed.) Mikrobiyoloji ve COVID-19. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.7-14.
Rabaan AA, Al-Ahmed SH, Haque S, Sah R, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med. 2020;28(2):174-184.
World Health Organization. (25/01/2023 tarihinde https://www.who.int/ adresinden ulaşılmıştır)
Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020 Apr;87(4):281-286. doi: 10.1007/s12098-020-03263-6.
Zou L, Ruan F, Huang M, Liang L, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-1179. doi: 10.1056/NEJMc2001737.
Tanaka H, Ogata T, Morisada K, et al. [Transmission of SARS-CoV-2 through contact with a SARS-CoV-2-infected individual in the presymptomatic or asymptomatic state in Japan: A case series]. Nihon Koshu Eisei Zasshi. 2021 Aug 11;68(8):550-558. Japanese. doi: 10.11236/jph.20-145.
Alp Ş, Ünal S. Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. Flora. 2020;25(2):111-120.
Carfì A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603-605. doi: 10.1001/jama.2020.12603. PMID: 32644129; PMCID: PMC7349096.
Memikoğlu O, Genç V. COVID-19. Ankara: Ankara Üniversitesi Basımevi; 2020.
T.C. Sağlık Bakanlığı COVID-19 (SARS-CoV-2 Enfeksiyonu) Erişkin Hasta Tedavisi (12/01/2022 tarihinde, https://covid19.saglik.gov.tr/TR-66926/eriskin-hasta-tedavisi.html adresinden ulaşılmıştır)
T.C. Sağlık Bakanlığı COVID-19 (SARS-CoV-2 Enfeksiyonu Antisitokin Antiinflamatuar Tedaviler, Koagülopati Yönetimi (7/11/2021 tarihinde https://covid19.saglik.gov.tr/TR-66341/antisitokin-antiinflamatuar-tedaviler-koagulopati-yonetimi.html adresinden ulaşılmıştır)
Beheshtirouy S, Khani E, Khiali S, et al. Investigational antiviral drugs for the treatment of COVID-19 patients. Arch Virol. 2022;167(3):751-805. doi: 10.1007/s00705-022-05368-z
Dhama K, Khan S, Tiwari R, et al. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020;33(4):e00028-20. doi: 10.1128/CMR.00028-20.
Zhang Y, Geng X, Tan Y, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020;127:110195. doi: 10.1016/j.biopha.2020.110195.
Tokgün PE, Dedeoğlu S, Tomatır AG. Yeni koronavirüs (covid-19) salgınıyla mücadelede moleküler biyoloji ve genetik çalışmaları. Sağlık Bilimlerinde İleri Araştırmalar Dergisi. 2022;5:41-49.
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-1567. doi: 10.1056/NEJMc2004973.
Ulasli M, Verheije MH, de Haan CA, et al. Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus. Cell Microbiol. 2010;12(6):844-61. doi: 10.1111/j.1462-5822.2010.01437.x.
Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2021 Apr;54(2):159-163. doi: 10.1016/j.jmii.2020.03.022. Epub 2020 Mar 31. PMID: 32265180; PMCID: PMC7138183.
Demirci, M, Ünlü Ö, Yiğin A, et al. SARS-CoV-2 Patogenezi ve Covid-19’da İmmun Yanıt. Turk Mikrobiyol Cemiy Derg. 2020;50(4):183-91.
Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98. doi: 10.1016/j.jare.2020.03.005.
Mengist HM, Kombe Kombe AJ, Mekonnen D, et al. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Semin Immunol. 2021 Jun;55:101533. doi: 10.1016/j.smim.2021.101533.
Fidan O, Mujwar S, Kciuk M. Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing. Mol Divers. 2023;27(1):463-475. doi: 10.1007/s11030-022-10440-6.
World Health Organization (18/01/2023 tarihinde, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance adresinden ulaşılmıştır)
NIH (26/01/2023 tarihinde, https://www.covid19treatmentguidelines.nih.gov/ adresinden ulaşılmıştır)
Yılmaz G. COVID-19: Antiviral Tedavi. SDÜ Tıp Fakültesi Dergisi. 2021; 28(COVİD-19 ÖZEL SAYI):79-85.
Yurdakök Dikmen B, Pat Y, Dilekoz E, et al. Covid-19 Farmakoterapisi. Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni. 2020; 11(2):80-114.
Ng TI, Correia I, Seagal J, et al. Antiviral Drug Discovery for the Treatment of COVID-19 Infections. Viruses. 2022;14(5):961. doi: 10.3390/v14050961.
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6.
Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020;32(3):107940. doi: 10.1016/j.celrep.2020.107940
Abd-Elsalam S, Salama M, Soliman S, et al. Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. Am J Trop Med Hyg. 2021;106(3):886-890. doi: 10.4269/ajtmh.21-0606.
Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int. 2020;14(5):881-883. doi: 10.1007/s12072-020-10077-3.
WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. doi: 10.1056/NEJMoa2023184.
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9.
Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305-315. doi: 10.1056/NEJMoa2116846.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-1826. doi: 10.1056/NEJMoa2007764.
Mahfouz MEM, Alharthi AA, Alsalmi NM, et al. Comparison of Different Antiviral Regimens in the Treatment of Patients with Severe COVID-19: A Retrospective Cohort. Medicina. 2023;59(2):260.
Kırbaş G. COVID-19 Tedavisinde Terapötikler. Dicle Tıp Dergisi. 2021; 48:187-197.
FDA. (03/06/2022 tarihinde, https://www.fda.gov/ adresinden ulaşılmıştır)
Syed YY. Molnupiravir: First Approval. Drugs. 2022;82(4):455-460. doi: 10.1007/s40265-022-01684-5.
Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Molnupiravir: A new candidate for COVID-19 treatment. Pharmacol Res Perspect. 2022;10(1):e00909. doi: 10.1002/prp2.909.
Sheahan, TP,Sims, AC, Zhou, S, et al. (). An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science translational medicine. 2020;12(541), eabb5883.
(12/06/2022 tarihinde, https://virological.org/t/mutagenic-antivirals-the-evolutionary-risk-of-low-doses/768 adresinden ulaşılmıştır)
Menéndez-Arias L. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2. J Biol Chem. 2021 Jul;297(1):100867. doi: 10.1016/j.jbc.2021.100867.
Fischer WA 2nd, Eron JJ Jr, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430. doi:10.1126/scitranslmed.abl7430.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509-520. doi: 10.1056/NEJMoa2116044.
Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Ann Med. 2022;54(1):516-523. doi: 10.1080/07853890.2022.2034936.
Extance A. Covid-19: What is the evidence for the antiviral Paxlovid? BMJ. 2022;377:o1037. doi: 10.1136/bmj.o1037. PMID: 35477536.
Chaplin S. Paxlovid: antiviral combination for the treatment of COVID‐19. Prescriber. 2022;33:31-33.
Stader F, Khoo S, Stoeckle M, et al. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. J Antimicrob Chemother. 2020;75(10):3084-3086. doi: 10.1093/jac/dkaa253.
Katzenmaier S, Markert C, Riedel KD, et al. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther. 2011 Nov;90(5):666-73. doi: 10.1038/clpt.2011.164.
(7/07/2022 tarihinde, https://covid19-druginteractions.org/prescribing_resources adresinden ulaşılmıştır)
Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593. doi: 10.1126/science.abl4784.
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408. doi: 10.1056/NEJMoa2118542.
Covıd-19 Tedavisinde Antiviraller. (12/01/2023 tarihinde, https://www.ttb.org.tr/userfiles/files/18ay_tedavi.pdf adresinden ulaşılmıştır
Madelain V, Nguyen TH, Olivo A, et al. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin Pharmacokinet. 2016;55(8):907-23. doi: 10.1007/s40262-015-0364-1.
Shannon A, Selisko B, Le N, et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv. 2020:2020.05.15.098731. doi: 10.1101/2020.05.15.098731.
Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 2020;83(6):534-536.
Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45-51. doi: 10.1016/S2055-6640(20)30016-9.
Anti-Viral Tedavisinde Güncel Durum. (16/01/2023 tarihinde https://www.ttb.org.tr/kutuphane/covid19-rapor_6/covid19-rapor_6_Part23.pdf adresinden ulaşılmıştır)
Lan SH, Lai CC, Chang SPet al. Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2022;15(6):759-766. doi: 10.1080/17512433.2022.2078701.
Rahman SMA, Kabir A, Abdullah ABM, et al. Safety and efficacy of favipiravir for the management of COVID-19 patients: A preliminary randomized control trial. Clin Infect Pract. 2022;15:100145. doi: 10.1016/j.clinpr.2022.100145.
Ergür FÖ, Yıldız M, Şener MU, et al. Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study. Sao Paulo Med J. 2022;140(3):372-377. doi: 10.1590/1516-3180.2021.0489.R1.13082021
Deng W, Yang C, Yang S, et al. Evaluation of favipiravir in the treatment of COVID-19 based on the real-world. Expert Rev Anti Infect Ther. 2022;20(4):555-565. doi: 10.1080/14787210.2022.2012155.
(10/06/2022 tarihinde, https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/appili-therapeutics-provides-update-on-phase-3-preseco-clinical-trial-evaluating-avigan-reeqonus adresinden ulaşılmıştır
Deng J, Zhou F, Hou W, Heybati K, et al. Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis. Future Virol. 2021:10.2217/fvl-2021-0066. doi: 10.2217/fvl-2021-0066.
Schoergenhofer C, Jilma B, Stimpfl T, et al. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19). Ann Intern Med. 2020;173(8):670-672. doi: 10.7326/M20-1550.
Eroğlu E, Tarakçı A, Çölkesen F, et al. COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi. J Contemp Med. 2020; 10(4):642-646.
RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4.
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. doi: 10.1056/NEJMoa2001282.
